Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes

Hemodialysis International

Volumn 18, Issue 2, 2014, Pages 433-442

  Nakamura, Yuya ^a,b   Tsuji, Mayumi ^b   Hasegawa, Hitomi ^b   Kimura, Kengo ^b   Fujita, Kiichiro ^a   Inoue, Michiyasu ^a   Shimizu, Tatsuo ^a   Gotoh, Hiromichi ^a   Goto, Yoshikazu ^a   Inagaki, Masahiro ^b   Oguchi, Katsuji ^b  

^a Saiyu Soka Hospital   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Diabetes; GLP 1; Hemodialysis; IL 6; Linagliptin; PGE2

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN; INTERLEUKIN 6; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTAGLANDIN E2; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

AGED; ALBUMIN BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; KIDNEY FAILURE, CHRONIC; PROCEDURES; RENAL REPLACEMENT THERAPY;

AGED; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; PURINES; QUINAZOLINES; RENAL DIALYSIS;

EID: 84898598759     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12127     Document Type: Article

References (58)

1. Shima K, Komatsu M, Kawahara K, Minaguchi J, Kawashima S. Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. Nephrology (Carlton). 2010; 15:632-638.
2. Ishimura E, Okuno S, Kono K, etal. Glycemic control and survival of diabetic hemodialysis patients - importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract. 2009; 83:320-326.
3. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: Role of incretin therapies. Drug Aging. 2008; 25:913-925.
4. Williams-Herman D, Round E, Swern AS, etal. Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis. BMC Endocr Disord. 2008; 8:14.
5. Shah Z, Kampfrath T, Deiuliis JA, etal. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011; 124:2338-2349.
6. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013; 10:73-84.
7. Kröller-Schön S, Knorr M, Hausding M, etal. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res. 2012; 96:140-149.
8. Schürmann C, Linke A, Engelmann-Pilger K, etal. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012; 342:71-80.
9. Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med. 2012; 12:995-1004.
10. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000; 15:953-960.
11. Kimple ME, Keller MP, Rabaglia MR, etal. The prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013; 62:1904-1912.
12. Mannucci E, Ognibene A, Cremasco F, etal. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001; 24:489-494.
13. Dobrian AD, Ma Q, Lindsay JW, etal. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab. 2011; 300:E410-E421.
14. Satoh-Asahara N, Sasaki Y, Wada H, etal. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013; 62:347-351.
15. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012; 35:2076-2082.
16. Matsubara J, Sugiyama S, Sugamura K, etal. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012; 59:265-276.
17. Gomez N, Touihri K, Matheeussen V, etal. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012; 14:14-21.
18. Lee YS, Park MS, Choung JS, etal. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia. 2012; 55:2456-2468.
19. Guo N, Sun J, Chen H, etal. Liraglutide prevents diabetes progression in prediabetic OLETF rats. Endocr J. 2013; 60:15-28.
20. Cechin SR, Pérez-Álvarez I, Fenjves E, etal. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant. 2012; 21:633-648.
21. Wu JD, Xu XH, Zhu J, etal. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011; 13:143-148.
22. Chaudhuri A, Ghanim H, Vora M, etal. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab. 2012; 97:198-207.
23. Hattori Y, Jojima T, Tomizawa A, etal. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010; 53:2256-2263.
24. Balas B, Baig MR, Watson C, etal. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007; 92:1249-1255.
25. Ahrén B, Landin-Olsson M, Jansson PA, etal. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89:2078-2084.
26. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001; 50:609-613.
27. Toft-Nielsen MB, Damholt MB, Madsbad S, etal. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86:3717-3723.
28. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29:46-52.
29. Yabe D, Kuroe A, Lee S, etal. Little enhancement of meal-induced glucagons-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest. 2010; 1:56-59.
30. Nakamura Y, Inagaki M, Shimizu T, etal. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: A 2-year study. Nephron Clin Pract. 2013; 123:46-51.
31. Makdissi A, Ghanim H, Vora M, etal. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012; 97:3333-3341.
32. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011; 58:157-166.
33. Thomas L, Eckhardt M, Langkopf E, etal. R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008; 325:175-182.
34. Watanabe S, Yamakami J, Tsuchiya M, etal. Anti-inflammatory effect of theophylline in rats and its involvement of the glucocorticoid-glucocorticoid receptor system. J Pharmacol Sci. 2008; 106:566-570.
35. Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes. 2005; 54:85-91.
36. Iwata H, Soga Y, Meguro M, etal. High glucose up-regulates lipopolysaccharide-stimulated inflammatory cytokine production via c-jun N-terminal kinase in the monocytic cell line THP-1. J Endotoxin Res. 2007; 13:227-234.
37. Meng ZX, Sun JX, Ling JJ, etal. Prostaglandin E2 regulates Foxo activity via the Akt pathway: Implications for pancreatic islet beta cell dysfunction. Diabetologia. 2006; 49:2959-2968.
38. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327-334.
39. Kim HJ, Higashimori T, Park SY, etal. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004; 53:1060-1067.
40. Ellingsgaard H, Hauselmann I, Schuler B, etal. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011; 17:1481-1489.
41. Shelbaya S, Amer H, Seddik S, etal. Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. Eur Rev Med Pharmacol Sci. 2012; 16:176-182.
42. Fujii Y, Abe M, Higuchi T, etal. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013; 14:259-267.
43. Ito M, Abe M, Okada K, etal. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J. 2011; 58:979-987.
44. Nowicki M, Rychlik I, Haller H, etal. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011; 65:1230-1239.
45. Nowicki M, Rychlik I, Haller H, etal. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011; 13:523-532.
46. Chan JC, Scott R, Arjona Ferreira JC, etal. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008; 10:545-555.
47. Kikuchi M, Abe N, Kato M, etal. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009; 83:233-240.
48. Nonaka K, Kakikawa T, Sato A, etal. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008; 79:291-298.
49. Raz I, Hanefeld M, Xu L, etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49:2564-2571.
50. Inaba M, Okuno S, Kumeda Y, etal. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007; 18:896-903.
51. Peacock TP, Shihabi ZK, Bleyer AJ, etal. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008; 73:1062-1068.
52. Nagayama H, Inaba M, Okabe R, etal. Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother. 2009; 63:236-240.
53. Viljoen M, de Oliveira AA, Milne FJ. Physical properties of the red blood cells in chronic renal failure. Nephron. 1991; 59:271-278.
54. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26(Suppl 1):S5-S20.
55. Inaba M, Maekawa K, Okuno S, etal. Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol. 2012; 78:273-280.
56. Freedman BI, Andries L, Shihabi ZK, etal. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol. 2011; 6:1635-1643.
57. Karamouzis I, Grekas D, Karamouzis M, etal. Physical training in patients on hemodialysis has a beneficial effect on the levels of eicosanoid hormone-like substances. Hormones. 2009; 8:129-137.
58. Schultze G, Maiga M, Neumayer HH, etal. Prostaglandin E2 promotes hypotension on low-sodium hemodialysis. Nephron. 1984; 37:250-256.